Da'atPep is the independent intelligence layer for peptides — continuously updated research, verified vendor data, and a transparent confidence score for every claim. No inventory. No hype. Just evidence, rated.
We'll send the first evidence brief before public launch.
Early access to the evidence database · No spam · Unsubscribe anytime
Every claim rated by the strength of its evidence — mechanism, animal, human, and long-term safety, scored separately.
Vendor pricing history, supply shifts, and demand signals across the market, updated continuously.
Suppliers scored on third-party COAs, certifications, and recall history — verified facts kept separate from rumor.
New papers, trials, and regulatory actions summarized the day they land, compared against prior literature.
In April 2026 the FDA moved to remove BPC-157 and several other peptides from its restricted compounding list, with a formal advisory review scheduled for July 23–24, 2026. Attention, money, and vendors are flooding in — and so is noise. Da'atPep exists to be the source people check first, because it is transparent about exactly how strong the evidence is.
Join the waitlist for early access to the database, the weekly evidence-and-market brief, and founding-member pricing.
We'll send the first evidence brief before public launch.